Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the
1990s. Pediatrics.1996;98(6 pt 1):1084-1088.
Zito JM, dosReis S, Safer DJ, Gardner J. Trends in psychotropic prescriptions for youths with Medicaid insurance
from a midwestern state: 1987-1995. Paper presented at: New Clinical Drug Evaluation Unit Meeting; June
1998; Boca Raton, Fla.
Greenhill LL. The use of psychotropic medication in preschoolers: indications, safety,
and efficacy. Can J Psychiatry.1998;43:576-581.
Minde K. The use of psychotropic medication in preschoolers: some recent developments. Can J Psychiatry.1998;43:571-575.
Rappley MD, Gardiner JC, Mullan PB, Wang J, Alvarez FJ. Psychotropic medications in children ages 1 to 3 with ADHD. Paper presented at: Pediatric Academic Societies Meeting (Joint Specialties
and Themes: Behavioral Pediatrics); May 4, 1998; New Orleans, La.
Pathiyal A, Miwa LJ, Sverdiov LS, Gardner E, Jones JK. Patterns of methylphenidate use. Paper presented at: American Society for Clinical Pharmacology and
Therapeutics; March 31, 1998; New Orleans, La.
Vitiello B, Jensen PS. Medication development and testing in children and adolescents: current
problems, future directions. Arch Gen Psychiatry.1997;54:871-876.
Grinfeld MJ. Psychoactive medications and kids: new initiatives launched. Psychiatric Times.1998;15:69.
Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, Fox M. Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol.1998;8:99-105.
Jensen PS, Vitiello B, Leonard H, Laughren TP. Child and adolescent psychopharmacology: expanding the research base. Psychopharmacol Bull.1994;30:3-8.
Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S. Short-term side effects of stimulant medication are increased in preschool
children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled
study. J Child Adolesc Psychopharmacol.1998;8:13-25.
Valentine J, Zubrick S, Sly P. National trends in the use of stimulant medication for attention deficit
hyperactivity disorder. J Paediatr Child Health.1996;32:223-227.
Safer DJ, Zito JM. Pharmacoepidemiology of methylphenidate and other stimulants for the
treatment of ADHD. In: Greenhill LL, Osman BB, eds. Ritalin: Theory
and Practice. 2nd ed. Larchmont, NY: MA Liebert Publishers; 2000:7-26.
Davilla RR, Williams ML, MacDonald JT. Clarification of policy to address the needs of children with attention
deficit hyperactivity disorders within general and/or special education. Memorandum from: US Dept of Education. Washington, DC: US Dept of
Education, Office of Special Education; September 16, 1991.
Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry.1997;36:539-544.
Swanson JM, Flockhart DA, Udrea D, Cantwell DP, Connor DF, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy
[letter]. J Child Adolesc Psychopharmacol.1995;5:301-304.
Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit
hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry.1996;35:599-605.
Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of Ritalin side effects. Pediatrics.1993;91:1101-1106.
Erickson SJ, Duncan A. Clonidine poisoning—an emerging problem: epidemiology, clinical
features, management and preventive strategies. J Paediatr Child Health.1998;34:280-282.
Kappagoda C, Schell DN, Hanson RM, Hutchins P. Clonidine overdose in childhood: implications of increased prescribing. J Paediatr Child Health.1998;34:508-512.
Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and
news reports about sudden death. J Child Adolesc Psychopharmacol.1995;5:157-166.
Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate and clonidine: a clinically sound medication
option vs. ill-advised. J Am Acad Child Adolesc Psychiatry.1999;38:614-619.
Pincus HA, Tanielian TL, Marcus SC.
et al. Prescribing trends in psychotropic medications: primary care, psychiatry,
and other medical specialties. JAMA.1998;279:526-531.
Foxman B, Valdez RB, Brook RH. Childhood enuresis: prevalence, perceived impact, and prescribed treatments. Pediatrics.1986;77:482-487.
Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry.1999;38:513-516.
Traversa G, Spila-Alegiani S, Arpino C, Ferrara M. Prescription of neuroleptics for children and adults in Italy. J Child Adolesc Psychopharmacol.1998;8:175-180.
Perrin JM, Kuhlthau K, McLaughlin TJ, Ettner SL, Gortmaker SL. Changing patterns of conditions among children receiving Supplemental
Security Income disability benefits. Arch Pediatr Adolesc Med.1999;153:80-84.
Hoagwood K, Jensen PS, Petti T, Burns BJ. Outcomes of mental health care for children and adolescents, I: a comprehensive
conceptual model. J Am Acad Child Adolesc Psychiatry.1996;35:1055-1063.
Vitiello B. Pediatric psychopharmacology and the interaction between drugs and
the developing brain. Can J Psychiatry.1998;43:582-584.